Current Status, Hotspots, and Future Directions of Research on the Treatment of Medullary Thyroid Carcinoma: A Bibliometric Analysis and Systematic Evaluation
Authors:
Preprint
- 29 October 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor for which some of the current treatments are controversial or still in the preliminary stages of research. Methods In this study, we searched the relevant literature in the Web of Science core database from its inception to June 2024. After screening, we performed bibliometric analyses using CiteSpace and Microsoft Excel. Results In total, 1694 articles were included in this study. In this field of research, American and Italian institutes lead in the number of papers. Wells SA is the most influential author in this field and J CLIN ENDOCR METAB is the most cited journal. Management, calcitonin, RET gene, surgery, antiangiogenic therapy, tyrosine kinase inhibitors, and peptide receptor radionuclide therapy are the hot research areas in the field of MTC treatment. Prophylactic thyroidectomy, targeted therapy, peptide receptor radionuclide therapy, and positron emission tomography are future research frontiers and global trends. Conclusions Research in this field has focused on surgical treatment, targeted therapy, radiotherapy, imaging and treatment management. Based on the results of the bibliometric analysis, a systematic assessment of the current status and future research directions of various treatment options for MTC was conducted, providing new ideas for further research in the field of MTC treatment.Keywords
All Related Versions
This publication has 43 references indexed in Scilit:
- The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid CancerEndocrine Practice, 2023
- Molecular basis and targeted therapy in thyroid cancer: Progress and opportunitiesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
- Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinomaAnnales d'Endocrinologie, 2022
- Multiple endocrine neoplasia type 2: A reviewSeminars in Cancer Biology, 2022
- Surgical aspects and controversies in the management of medullary thyroid cancerIrish Journal of Medical Science (1971 -), 2022
- Clinical utility of 177Lu‐DOTATATE PRRT in somatostatin receptor‐positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicityHead & Neck, 2019
- The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: A systematic reviewRadiotherapy and Oncology, 2019
- Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPAEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Systemic treatment and management approaches for medullary thyroid cancerCancer Treatment Reviews, 2016
- Long-Term Follow-up in Medullary Thyroid Carcinoma2015